"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Cinobac® (Cinoxacin, USP) is a synthetic antibacterial agent for oral administration. Cinoxacin, quinolone, is 1-ethyl-1,4-dihydro-4-oxo-[1,3] dioxolo [4,5-g] cinnoline-3-carboxylic acid and occurs as white or very light-yellow, needle-shaped crystals. Cinobac (cinoxacin) is available as 250-(0.95 mmol) and 500-mg (1.9 mmol) capsules. These capsules also contain D & C Yellow No. 10, F D & C Blue No. 1, F D & C Red No. 3, F D & C Yellow No. 6, gelatin, silicon dioxide, silicone fluid, sodium lauryl sulfate, starch, titanium dioxide, and other inactive ingredients.
The molecular formula is C12H10N2O5 and the molecular weight is 262.22.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Cinobac Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.